Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

By Hofer Silvia   Elandt Katarzyna   Greil Richard   Hottinger Andreas F.   Huber Urs   Lemke Dieter   Marosi Christine   Ochsenbein Adrian   Pichler Josef   Roelcke Ulrich   Weder Patrik   Zander Thilo   Wick Wolfgang   Weller Michael  

Acta Oncologica, Vol. 50, Iss. 5, 2011-06 ,pp. : 630-635

Informa Healthcare

Access to resources Recommend Favorite

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival

By Chen Christina   Huang Raymond   MacLean Ainsley   Muzikansky Alona   Mukundan Srinivasan   Wen Patrick   Norden Andrew  

Journal of Neuro-Oncology, Vol. 115, Iss. 2, 2013-11 ,pp. : 267-276

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer

By Degirmenci M.   Karaca B.   Gorumlu G.   Durusoy R.   Demir Piskin G.   Bozkurt M.   Cirak Y.   Tunali D.   Karabulut B.   Sanli U.   Uslu R.  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 585-591

Humana Press, Inc

Access to resources Recommend Favorite

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

By Poulsen Hans Skovgaard   Grunnet Kirsten   Sorensen Morten   Olsen Preben   Hasselbalch Benedikte   Nelausen Knud   Kosteljanetz Michael   Lassen Ulrik  

Acta Oncologica, Vol. 48, Iss. 1, 2009-01 ,pp. : 52-58

Informa Healthcare

Access to resources Recommend Favorite

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen

By Parekh Chintan   Jubran Rima   Erdreich-Epstein Anat   Panigrahy Ashok   Bluml Stefan   Finlay Jonathan   Dhall Girish  

Journal of Neuro-Oncology, Vol. 103, Iss. 3, 2011-07 ,pp. : 673-680

Springer Publishing Company

Access to resources Recommend Favorite